• HIV;
  • semen;
  • vaginal inflammation;
  • vaginal innate immunity


  1. Top of page
  2. Abstract
  3. Introduction
  4. Conclusions
  5. Acknowledgements
  6. References

Semen deposition results in modulated immunity and an inflammatory response of the genital mucosa, which promotes conditions facilitating conception and pregnancy. These semen-induced alterations in the female reproductive tract can also have implications for the sexual transmission of viral infections such as HIV-1. Semen is not only a vector for HIV-1 but also a carrier for pro- and antiviral factors. Semen induces significant mucosal changes upregulating gene, and transcription factors leading to recruitment and activation of HIV target cells, stimulation of HIV replication and potentiation of Toll-like receptor responses. Although more research is needed to clearly elucidate the resulting collective effects of all these factors, semen modulation of the cervicovaginal microenvironment and immune system appears to lead, through multiple mechanisms, to mucosal changes facilitating viral entry and replication, likely resulting in enhanced susceptibility to acquire HIV-1 infection.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Conclusions
  5. Acknowledgements
  6. References

Role of Semen in HIV Transmission

Human seminal plasma is a complex fluid that contains multiple bioactive molecules and structures that not only provide medium for sperm transport and survival, but also induce changes in the female reproductive tract (FRT). Semen deposition results in modulated immunity and an inflammatory response of the genital mucosa, which promotes conditions that facilitate conception and pregnancy.[1, 2] These semen-induced alterations in the FRT can also have implications for the sexual transmission of viral infections such as HIV-1. Therefore, there is a pressing need to further characterize the impact of semen on the regulation of mucosal epithelial and immune cells in the FRT.

Thirty years after it was first identified, HIV still remains a major global health pandemic, with approximately 35 million people currently living with HIV worldwide.[3] In 2012 alone, there were 2.3 million new infections and 1.6 million deaths due to HIV/AIDS worldwide.[3] Notably, HIV is the leading cause of death and disease for women of reproductive age globally[4], and heterosexual transmission is the primary mode of infection in the developing world.[3, 5]

While unprotected sexual intercourse represents the primary mode of transmission for HIV-1 infection, the estimated rates per coital act are much lower than might be expected to efficiently convey the virus through heterosexual contact. The often cited probability of male-to-female transmission is approximately 1–2 infections per 1000 unprotected vaginal acts[6, 7]; however, viral transmission could be even higher than these epidemiological estimates, based on the phase of infection in the male, seminal viral load, no use of antiretrovirals, and the presence of concurrent sexually transmitted infections (STIs) in the FRT.[8-11] Heterosexual transmission of HIV-1 likely involves a complex interplay of facilitatory and inhibitory factors that mediate the risk of infection for any given sexual encounter.[12]

The major vector for male-to-female HIV-1 transmission during receptive vaginal sex is semen. In terms of reproduction, seminal fluid was initially considered to be merely a passive conduit that allowed for spermatozoa to successfully traverse the female genital tract in order to initiate conception and pregnancy. However, following insemination, there is a rapid reaction in FRT epithelial cells that resembles an inflammatory response. This immediate and dramatic post-coital pro-inflammatory influx has been well characterized in several mammalian species, including humans,[1, 13, 14] and has been postulated to promote fertilization, conception, and pregnancy.[15] In addition, this mucosal reaction also encompasses local cellular changes that may impact susceptibility to HIV-1 infection.[16, 17] The exact nature of seminal modulation of viral transmission across the genital mucosa remains controversial, and semen-mediated effects both promote and inhibit infection.[17] Biologic factors of the FRT that condition acquisition of HIV infection in women include the following: alterations in epithelial integrity, immune cell recruitment and activation, inflammation, innate antimicrobial activity, adaptive immunity, mucus barrier, and microbiota. Semen may facilitate or inhibit mucosal HIV infection through multiple mechanisms, involving one or more of the above-mentioned factors.

Mechanism of Sexual Transmission of HIV

Once HIV-1 is deposited within the female genital tract, the virus must transverse the mucosal epithelium to gain access to an array of potential cellular targets. These include dendritic cells (DCs), Langerhans' cells (LCs), macrophages, and CD4+ T cells.[18] The primary target of HIV-1 appears to be CD4+ T cells, in which productive infection occurs through sequential interaction of HIV envelope proteins with the CD4 receptor and CCR5/CXCR4 coreceptors. The initial routes of the virion transmission to the CD4+ T cell, however, have not been clearly elucidated.

The cervicovaginal epithelium displays a heterogeneous tissue architecture that likely requires HIV-1 virions to utilize multiple strategies in order to gain entry to basal compartments where viral targets are more abundant. The vagina and ectocervix are covered by a multilayered, stratified squamous epithelium, while the endocervix is lined with a single-layered columnar epithelium. Thus, the intact vaginal and ectocervical epithelium provide a much greater protective barrier to virion transmission as compared to the endocervix, but also affords an enhanced surface area for potential penetration.[19] Furthermore, the transformation zone (the epithelial junction between squamous ectocervix and columnar endocervical) may be particularly susceptible to HIV entry, given both its unique structure and enhanced population of CD4+ T cells.[19-21] The mucosal barrier may be breached via microabrasions resulting from sexual intercourse or concurrent inflammatory conditions of the genital mucosa.[22, 23]As discussed below, the cervicovaginal epithelium not only acts as a barrier to virion entry, but it also reacts to virus interaction with secretion of immune mediators which influence the primary infection.[24, 25] Although controversial, some evidence exists indicating genital epithelial cells may transport and even become infected by HIV.[26]

Direct productive infection of CD4+ T cells has been demonstrated in vivo, using SIV macaque models, as well as in ex vivo experiments in which epithelial sheets were exposed to HIV-1.[27] At the same time, there is evidence accumulating that infection of CD4+ T cells occurs more efficiently when mediated by DCs present in genital mucosal and submucosal compartments.[28-30] These cells capture HIV-1 envelope proteins and allow the virus to cross the cervicovaginal epithelial barrier. The intra-epithelial processes of the LCs help convey HIV to the submucosal lymphocytes, and following productive infection of these CD4+ T cell populations; the virus is able to propagate and disseminate via lymphatic mechanisms.[31, 32]

Studies from non-human primates suggest that SIV penetrates the cervicovaginal epithelium and is able to infect a small population of cells within an hour.[30, 33] Recently, human cervical explant and in vivo macaque exposure studies using photoactivatable-labeled virions have shown that HIV-1 can readily penetrate both intact columnar and squamous epithelium; however, the cervicovaginal epithelium is highly susceptible to viral infiltration via ‘diffusive percolation’ through interstitial spaces, while HIV-1 entry is impeded at the endocervical epithelium by mucus production.[34]

Single-genome amplification and phenotypic analysis of blood samples taken during the acute phase of infection have determined that more than 75% of heterosexual transmission of HIV-1 arises from single founder viral variant.[35, 36] Concurrent infections and inflammation appear to facilitate infection by more than one viral variant.[37] While the exact mechanisms are not fully understood, sexual transmission of HIV-1 at the cervicovaginal mucosa requires minimal acute exposure for systemic propagation of infection.

Impact of Sexual Intercourse on FRT Microenvironment

In addition to the deposition of semen, a process that facilitates a pro-inflammatory response and expansion of regulatory T cells,[1, 38, 39] the act of intercourse itself induces transient changes in the FRT microenvironment. While consensual intercourse does not appear to alter the number of vaginal epithelial layers or subepithelial lymphocytes,[40] mucosal microabrasions and lacerations have been observed in a majority of women by colposcopy up to 80 hrs after coitus.[22, 41] Mucosal damage and inflammation are much more common after sexual assault and, among other factors, may underlie the reported increased transmission of HIV under these circumstances.[42, 43] During sexual activity, the vagina undergoes anatomic and physiological changes. Engorgement of the vaginal wall raises pressure inside capillaries and increases blood flow, rugae increase frictional tension, and lubricative plasma transudated through the vaginal epithelium forms a film that covers the vaginal lumen.[44] These physical changes can alter the surface area of the vagina, affecting the distribution of cervicovaginal secretions and exogenously applied microbicide, that is, HIV preventative products.[45, 46]

Sexual intercourse can also affect the microbiota of the FRT. Frequent intercourse is associated with greater fluctuation in vaginal flora.[47] Women reporting more than five penile/vaginal acts within the past 90 days had higher quantities of hydrogen peroxide (H2O2)-producing lactobacilli,[48] which are thought to be protective against reproductive tract infections (RTIs), including bacterial vaginosis (BV) and HIV.[49] However, other studies have shown that the number of partners and frequency of intercourse are not associated with H2O2-producing lactobacilli colonization.[50, 51] Semen does not appear to be the driving force in impacting FRT microbiota, as there is no difference in vaginal lactobacilli species following intercourse with or without a condom.[40] More refined detection methods, however, have demonstrated that consistent condom use results in increased expression of L. crispatus, one of the strongest H2O2-producing species.[52]

Semen-associated Factors Modulating HIV Transmission

There is evidence that semen both enhances and impedes HIV-1 infectivity.[17, 53] Seminal plasma (SP) contains several inhibitory factors that act to suppress mucosal transmission of HIV-1. Seminal fluid and whole semen have demonstrated anti-HIV activity in vitro in T-lymphocyte cell lines.[54] Cationic polypeptides contained in seminal plasma[55] and reactive oxygen species produced by seminal leukocytes and spermatozoa[56] provide intrinsic antiviral activity against HIV-1. Seminal plasma also blocks the attachment of HIV-1 to DC-SIGN, thus preventing viral transfer to CD4+ target cells in vitro.[57, 58] Similarly, SP protects target lymphocytes from HIV-1 infection by decreasing cell surface expression of CD4 and CXCR4, although CCR5 expression is increased.[59] There is also preliminary evidence to suggest that seminal fluid is capable of increasing female genital tract epithelial monolayer integrity, thereby strengthening the physical barrier to infection as well.[60]

While some components of seminal fluid aggregate to provide an innate defense mechanism against HIV-1 infection, there is also mounting evidence of proviral semen-mediated effects as well. It has long been known that following ejaculation, semen raises the normally acidic pH of vaginal fluid to 7.0 or higher within 30 s, and this neutralization of the vaginal lumen can persist for at least 2 hrs.[61, 62] The buffering capacity of semen may help to maintain conditions that are conducive to HIV-1 stability and infection.[63-66] HIV-1 infection can be enhanced by amyloid fibrils formed in semen by peptides, called semen-derived enhancer of viral infection (SEVI), as well as fibrils formed by semenogelin fragments. While SEVI's biologic function is not known, in vitro, these amyloid fibrils capture HIV virions and promote their attachment to CD4+ T cells.[26, 67-71] Heparan sulfate on spermatozoa also binds HIV and transmits the virus to dendritic cells.[72] Furthermore, complement activation in seminal fluid generates C3 cleavage and augments HIV-1 infection in epithelial cells.[73] In vaginal epithelial cells, SP induces the secretion of CCL20 and subsequent recruitment of LCs.[74] Similarly, female genital epithelial cells treated with semen from acutely infected men produce heightened levels of pro-inflammatory cytokines, and these factors increased HIV-LTR activation in infected T cells.[75] Seminal fluid itself is enriched with pro-inflammatory cytokines and chemokines that can contribute to enhanced HIV replication.[76] Finally, two in vivo studies in non-human primates indicate that seminal plasma has no significant effect on transmission rate following intravaginal inoculation with SIV. However, animals were more likely to be persistently viremic following inoculation with low doses of virus in the presence of SP as compared to without.[77, 78]

Seminal Plasma and Female Genital tract Immune Response

The inflammatory response caused by SP, while being favorable for physiological reproductive functioning of FRT, that is, facilitating embryo implantation and pregnancy, may, at the same time, provide settings that modify the susceptibility of FRT to HIV-1.[13] Inflammation and generalized immune activation are seen as conditions favoring HIV-1 sexual transmission at the cervicovaginal mucosa due to the attraction of HIV-1 target cells, increased expression of viral receptors, and alteration of epithelial barrier integrity which would facilitate viral entry.[28, 79, 80]

Several other immunologic factors are present in semen at remarkably high levels, including IL-7, TGF-β, and prostaglandins of E series (PGE).[76, 81, 82] These immune mediators have both pro- and anti-inflammatory effects. Understanding the interaction of these various immunologic factors contained in seminal plasma with the genital mucosa has important implications for determining the impact of semen on mucosal propensity to HIV-1 infection. Importantly, immunologic effects of semen are detected not only within genital mucosa, but also at more distant sites, like FRT-related draining lymph nodes,[15] which may also impact host HIV-1 susceptibility.

SP induces cervicovaginal epithelial expression of pro-inflammatory factors

Human seminal plasma induces an array of pro-inflammatory cytokines, while downregulating innate antiviral factors like SLPI, in cervical cell lines and explants.[14, 83] Numerous genes associated with inflammation and immune response pathways are also upregulated in ectocervical tissues following unprotected coitus.[38] Recently, post-coital upregulation of inflammation-related cytokines and chemokines including GM-CSF, IL-1α, IL-1β, CXCL1, CXCL2 (MIP-2α), CXCL3 (MIP-2β), CCL-20 (MIP-3α) as well as a key inflammatory enzyme, cyclooxygenase 2 (COX-2), was demonstrated in the human cervix by microarray analysis,[38] in agreement with in vitro cervical cell response to SP.[14] In our laboratory, we performed microarray gene expression analysis of vaginal epithelial cells exposed to SP in vitro and found upregulation of many inflammation-related genes.[16, 84] We also demonstrated that semen strongly potentiates vaginal epithelial TLR activation induced by their ligands.[16] Considering that physiological levels of pro-inflammatory cytokines enhance susceptibility to HIV-1 infection fivefold to eightfold in cervical explant tissues,[85] this heightened inflammatory response could have important ramifications for viral transmission.

SP induces CCL20, a chemokine for CCR6 receptor expressed by HIV target cells

CCL20 secretion is upregulated both in cervical[14, 38] and vaginal[84] epithelium by seminal plasma. CCL20 is the only chemokine ligand for the CCR6 receptor, expressed by subsets of DCs, particularly precursors of LCs, and memory T cells including CD4+ Th17 T cells.[74, 86, 87] LCs, present in cervicovaginal mucosa, are among the primary targets of HIV-1/SIV.[30, 31, 88, 89] LCs are able to capture HIV-1 virions and transport them to the draining lymph nodes where the virions can be transmitted to T cells for productive infection,[88-90, 27] although there is some evidence to suggest viral particles captured by LCs are internalized and rendered incapable of infection.[90] In women, semen-enhanced infiltration of LCs into the genital epithelium has been demonstrated.[38] SP has been shown to induce secretion of the chemokine CCL20 in vaginal epithelial cells via NFκB signaling pathways.[74] In vitro, secreted CCL20 promotes the recruitment of precursor LCs that are capable of being infected by X4 and R5 tropic HIV strains. Likewise, intravaginal SIV inoculation increases CCL20 expression in endocervical epithelium, and inhibition of CCL20 prevents mucosal transmission of infection in macaque models.[25]

CCL20/CCR6 communication is involved in the recruitment of CCR6-expressing memory CD4+Th17 cells observed in diverse tissues.[91-93] CD4+Th17 cells are a subset of pro-inflammatory helper T cells that are essential in specific settings of inflammation and elicit protective immune responses to parasitic infections.[93] These cells co-express CCR5 and are highly permissive for HIV-1 replication in vitro. CD4+Th17 cells are among the earliest HIV/SIV preferential targets and play a crucial role in HIV pathogenesis.[86, 94-97] In contrast to the significant semen-induced increase in DCs and LCs in the female genital epithelium, no or modest increases in FRT CD4+ T cell density have been detected following semen exposure.[23, 38] At the same time, due to CCL20, a small number of these highly susceptible to HIV-1 CD4+ Th 17 cells can infiltrate the mucosal epithelium or migrate to local lymph nodes. Taken together, it can be speculated that semen-enhanced CCL20 secretion may increase male-to-female HIV-1 transmission through recruitment of LC precursors and CD4+ T cells to genital tissues.

In contrast, CCL20 at relatively high concentrations has demonstrated anti-HIV-1 activity in primary uterine and fallopian tube epithelial cells, but only when the virus was incubated with CCL20 prior to infection.[98] Although this study does not reflect the contribution of SP, it does indicate that CCL20, particularly in the upper FRT, has endogenous antimicrobial properties as well. It will be important to determine whether semen has the same potentiating effects of CCL20 secretion in these epithelial cells, and whether this ultimately plays a protective or permissive role in HIV-1 transmission.

SP contains abundant immunomodulatory mediators

In addition to inducing pro-inflammatory factors within the FRT, semen itself contains numerous factors that can modulate seminal and mucosal immune responses. They include cytokines, chemokines, growth factors, prostaglandins, and immunoglobulins.[99, 100] In several extensive studies that have assessed immunologic factors in semen, the cytokines/chemokines IL-1α, IL-7, IL-8, MIP-3α, MCP-1, MIG and IP-10, SDFβ1 and TGF-β were enriched in the semen of HIV-uninfected and HIV-infected men[81, 101, 76, 102] compared with their blood levels. In the seminal plasma of men infected with HIV, upregulation of specific subset of pro-inflammatory factors in the seminal plasma was demonstrated in several studies.[76, 82, 101] Furthermore, there is increased interaction between individual cytokines, resulting in ‘cytokine networks’ that may be less able to effectively respond to viral infection due to their heightened correlated activity.[101] In support of this, seminal plasma from HIV-positive men in the acute phase of infection has been reported to contain much higher concentrations of an array of pro-inflammatory cytokines and chemokines, as compared to uninfected or chronically infected samples.[75] Furthermore, endometrial epithelial cells treated with seminal plasma from these acutely HIV-infected men produced increased levels of the pro-inflammatory cytokines IL-1α, IL-6, and TNF-α, and this immunomodulatory response increased HIV-1 replication in CD4+ T lymphocytes.[75] Thus, there appear to be qualitative and quantitative changes in semen factors following HIV-1 infection that could impact viral propagation via heterosexual transmission in the FRT.

SP is highly enriched in IL-7

Interleukin-7 (IL-7) is a key cytokine critical in maintaining T-cell homeostasis. Interactions of IL-7 and IL-7 receptor chain (IL-7Rα) are central in thymopoiesis and regulation of peripheral T cells.[103] This homeostatic regulatory mechanism involves feedback suppression of IL7Rα expression by IL-7.[104] Notably, IL-7 is highly abundant in the semen of fertile men (200 times its level in blood) and significantly elevated in semen of HIV-1-infected males.[81, 82] Increased IL-7 plasma levels were also observed in HIV-infected individuals.[105, 106] In a recent study, it has been demonstrated that in ex vivo CV and lymphoid tissues, IL-7, at concentrations comparable to those found in semen, stimulated proliferation and impeded apoptosis of CD4+ T cells, which resulted in enhanced HIV-1 replication.[107] Increase in the expression of the anti-apoptotic protein Bcl2 in response to IL-7 was implicated in preserving infected CD4+ T cells.[107, 108] Taken as a whole, IL-7 appears to exert a protective effect on target memory and HIV-infected cells that may promote the establishment of a productive infection in female vaginal tract.

SP contains large amounts of TGF-β

TGF-β is a ubiquitous cytokine, and one of the key factors implicated in modulation of host defense. Three isoforms of TGF-β (TGF-β1, TGF-β2, and TGF-β3) are abundantly expressed in many tissues, with TGF-β1 being dominant in the immune system. TGF-β promotes differentiation of naïve CD4+ cells to FOXP3-expressing regulatory T cells (Treg) cells in the presence of IL-2, and to HIV-1 preferential targets, CD4+Th17 cells, in the presence of IL-6. Thus, TGF-β is involved in regulating the balance between pro-inflammatory and suppressive immune cell lineages contributing to immune homeostasis,[109] which can be altered depending on environmental conditions, including the presence of other cytokines or prostaglandins. TGF-β, abundantly present in semen (fivefold that of serum), has been suggested to be one of the major factors related to induction of immune tolerance in FRT, mediated through the differentiation of Treg cells and suppression of NK cells.[100, 110] TGF-β also acts as a pro-inflammatory factor and induces production of GM-CSF, IL-6, and IL-8 in ectocervical immortalized cells (Ect1) in a dose-dependent manner.[111] Microarray analysis of genes induced in Ect1 cells by TGF-β3 revealed upregulation of a number of pro-inflammatory cytokine and chemokine genes that have also been shown to be upregulated in cervical cells by SP/semen in vitro and in vivo.[111]

Already high in healthy men, TGF-β levels are found to be moderately increased in SP during acute HIV infection and strongly increased during the chronic stage.[75] TGF-β has long been implicated in the regulation and pathogenesis of HIV-1.[112-114] In vitro experiments have demonstrated that TGF-β may act as a suppressor or stimulator of HIV-1, including direct activation of HIV-1-LTR, depending on timing of treatment, cell type, and virus strain.[112, 115-117] It has been proposed that overexpression of TGF-β can result in alteration of its functions from protective to pathogenic ones.[112]

The immunomodulatory/inflammatory response induced in the FRT by the semen TGF-β may affect HIV-1 susceptibility. Semen TGF-β could facilitate HIV-1 propagation by suppressing innate immune activity of NK cells and eliciting inflammatory response in FRT, including upregulation of inflammatory cytokines and promotion of differentiation of CD4+ Th17 cells. However, further work is needed to fully determine the biologic effect on the FRT mucosa of semen-derived TGF-β.

SP contains large amounts of prostaglandins of the E series (PGE)

Prostaglandins are potent immunomediators involved in numerous physiological and pathogenetic processes. PGE2, the most studied prostaglandin, is capable of modulating immune cell functions at multiple levels.[118-121] PGE2 suppresses effector functions of macrophages and neutrophils, and impairs cytotoxic capacity of CTLs and NK cells. PGE2 is involved in the activation of DCs, but suppresses their ability to attract T cells.[122, 123] In cervical explants, PGE2 inhibits release of secretory leukocyte protease inhibitor (SLPI), an anti-HIV defense factor.[83]

The concentration of semen PGE is several orders of magnitude higher than that of serum, although there is a high interindividual variability in the semen PGE content,[124] In our laboratory, we found that SP stimulates expression of PTGS2 (COX-2) gene in vaginal epithelial cells and identified PGE2 as the seminal factor responsible for mediating this induction.[16] Seminal plasma has been shown to upregulate COX-2 expression in cervical adenocarcinoma cells.[125] Importantly, COX-2 is also known to be induced in human vaginal epithelial cells in response to TLR ligands and pro-inflammatory compounds,[126] an effect that is potentiated in the presence of SP.[16] Enhanced mucosal expression of COX-2, induced by pro-inflammatory stimuli and further increased by semen PGE2, may have implications for HIV-1 transmission in the FRT and explain, in part, the costimulatory effect of cervicovaginal infections.

SP triggers NF-κB translocation and gene transcription

NF-κB is an inducible transcription factor that plays a crucial role in regulating innate immune responses, as well as the induction of HIV-1 gene expression. Following exposure to SP in vitro, microarray gene expression analysis of vaginal epithelial cells revealed upregulation of many inflammation-related genes.[16, 84] Functional analysis of this gene set indicated inflammatory response as the top biofunction, and NF-kB activation as a central mechanism implicated in gene dysregulation.[84] Activated NF-kB signaling pathway is central in inflammation and a powerful component in induction of HIV-1 gene expression.[127] NF-kB activation stimulates HIV-1 replication by directly activating the HIV-1 promoter, LTR, and by inducing synthesis and secretion of chemokines which attract and activate new HIV-1 target cells.[127]

We have demonstrated that SP-induced COX-2 expression in vaginal cells is mediated by NFκB and MAPK signaling pathways. Activation of NFκB in VK-2 cells occurred within 30 min of treatment with SP, as evidenced by degradation of IkB-α in the cytoplasm and abrogated expression of COX-2 in the presence of NFκB pathway-specific inhibitor.[16] Therefore, SP-induced NFκB signaling mechanisms mediate molecular changes which may enhance mucosal susceptibility to HIV-1 infection.

Taken as a whole, the role of semen in HIV transmission clearly extends beyond that of a passive transporter for cell-free and cell-associated virus. The contribution of seminal fluid to male-to-female sexual transmission remains equivocal, and the resulting collective immunomodulatory effect of these various SP factors at the mucosa is not clear. More evidence is needed to clearly elucidate whether SP complex interaction with the mucosa leads to changes mediating enhanced susceptibility to HIV infection. Studying the resulting effect of SP on HIV/SHIV infections of human cervical tissue explants and macaques represents key experiments to provide some of these missing data.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Conclusions
  5. Acknowledgements
  6. References

Sexual intercourse modifies the cervicovaginal microenvironment by increasing the mucosal surface, causing microabrasions, and increasing the blood flow and cervicovaginal fluids. In addition, it introduces semen. Semen is a biologically complex fluid evolutionary selected to protect spermatozoa and increases their chances of survival and egg fertilization. HIV has hijacked this mechanism and utilizes semen as its main vector. But semen is not only the most important vector of HIV in sexual transmission, it also is an active modulator of the mucosal immune system bringing pro- and anti-inflammatory factors and inducing pro- and antiviral mediators and mucosal changes. Semen contains abundant quantities of TGF-B, IL-7, and PGE, among other potent immune mediators. It induces gene expression in cervicovaginal epithelial cells and tissues leading to upregulation and activation of pro-inflammatory genes and factors such as COX-2, CCL20, IL-8, and NFkB. It also potentiates Toll-like receptor mediated responses.

Although more research is needed to clearly elucidate the resulting collective effects of all these factors, we believe that semen modulation of the cervicovaginal microenvironment and immune system leads to mucosal changes which, through multiple mechanisms, may facilitate recruitment and/or activation of HIV target cells and increased viral entry and replication, likely resulting in enhanced susceptibility to acquire HIV-1 infection.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Conclusions
  5. Acknowledgements
  6. References

The work of the authors has been supported by grants of the US International Agency for Development (GPO-A-00-08-00005-00), the National Institute of Allergy and Infectious Diseases (Y1-AI-1756-01), and the Bill and Melinda Gates Foundation (ID 41266). The views of the authors do not necessarily reflect those of these funding agencies.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Conclusions
  5. Acknowledgements
  6. References
  • 1
    Robertson SA: Seminal plasma and male factor signalling in the female reproductive tract. Cell Tissue Res 2005; 322:4352.
  • 2
    Schuberth HJ, Taylor U, Zerbe H, Waberski D, Hunter R, Rath D: Immunological responses to semen in the female genital tract. Theriogenology 2008; 70:11741181.
  • 3
    UNAIDS: Global Report: UNAIDS Report on the Global AIDS Epidemic. Geneva, UNAIDS, 2013.
  • 4
    WHO: Women's Health Fact Sheet No. 334. Geneva, WHO, 2013.
  • 5
    Shattock RJ, Moore JP: Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003; 1:2534.
  • 6
    Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, vanCott T, Quinn TC: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:11491153.
  • 7
    Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, Kiarie J, Inambao M, Kilembe W, Farquhar C, Celum C: Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 2012; 205:358365.
  • 8
    Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, Nalugoda F, Wabwire-Mangen F, Meehan MP, Quinn TC: Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J InfectDis 2005; 191:14031409.
  • 9
    Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M: Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118129.
  • 10
    Galvin SR, Cohen MS: The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:3342.
  • 11
    Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, Goh LE, Cohen MS: Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:17851792.
  • 12
    Hladik F, Doncel GF: Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res 2010; 88 (Suppl 1):S3S9.
  • 13
    Robertson SA: Seminal fluid signaling in the female reproductive tract: lessons from rodents and pigs. J Anim Sci 2007; 85:E36E44.
  • 14
    Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA: Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod 2007; 13:491501.
  • 15
    Robertson SA, Guerin LR, Moldenhauer LM, Hayball JD: Activating T regulatory cells for tolerance in early pregnancy – the contribution of seminal fluid. J Reprod Immunol 2009; 83:109116.
  • 16
    Joseph T, Zalenskaya IA, Sawyer LC, Chandra N, Doncel GF: Seminal plasma induces prostaglandin-endoperoxide synthase (PTGS) 2 expression in immortalized human vaginal cells: involvement of semen prostaglandin E2 in PTGS2 upregulation. Biol Reprod 2013; 88:13.
  • 17
    Doncel GF, Joseph T, Thurman AR: Role of semen in HIV-1 transmission: inhibitor or facilitator? Am J Reprod Immunol 2011; 65:292301.
  • 18
    McKinnon LR, Kaul R: Quality and quantity: mucosal CD4+ T cells and HIV susceptibility. Curr Opin HIV AIDS 2012; 7:195202.
  • 19
    Hladik F, McElrath MJ: Setting the stage: host invasion by HIV. Nat Rev Immunol 2008; 8:447457.
  • 20
    Pudney J, Quayle AJ, Anderson DJ: Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone 1. Biol Reprod 2005; 73:12531263.
  • 21
    Kaushic C: HIV-1 infection in the female reproductive tract: role of Interactions between HIV-1 and genital epithelial cells. Am J Reprod Immunol 2011; 65:253260.
  • 22
    Norvell MK, Benrubi GI, Thompson RJ: Investigation of microtrauma after sexual intercourse. J Reprod Med 1984; 29:269271.
  • 23
    Prakash M, Patterson S, Gotch F, Kapembwa MS: Recruitment of CD4 T lymphocytes and macrophages into the cervical epithelium of women after coitus. Am J Obstet Gynecol 2003; 188:376381.
  • 24
    Hickey DK, Patel MV, Fahey JV, Wira CR: Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol 2011; 88:185194.
  • 25
    Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT: Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458:10341038.
  • 26
    Micsenyi AM, Zony C, Alvarez RA, Durham ND, Chen BK, Klotman ME: Postintegration HIV-1 infection of cervical epithelial cells mediates contact-dependent productive infection of T cells. J Infect Dis 2013; 208:17561767.
  • 27
    Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ: Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26:257270.
  • 28
    Shey MS, Garrett NJ, McKinnon LR, Passmore JA: The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene? Innate Immun 2013; [Epub ahead of print].
  • 29
    Wang JH, Janas AM, Olson WJ, Wu L: Functionally distinct transmission of human immunodeficiency virus type 1 mediated by immature and mature dendritic cells. J Virol 2007; 81:89338943.
  • 30
    Hu J, Gardner MB, Miller CJ: Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74:60876095.
  • 31
    Hladik F, Hope TJ: HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009; 6:2028.
  • 32
    Ballweber L, Robinson B, Kreger A, Fialkow M, Lentz G, McElrath MJ, Hladik F: Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells. J Virol 2011; 85:1344313447.
  • 33
    Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L, Compton L, Duan L, Shore MD, Zupancic M, Busch M, Carlis J, Wolinsky S, Haase AT: Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79:92179227.
  • 34
    Carias AM, McCoombe S, McRaven M, Anderson M, Galloway N, Vandergrift N, Fought AJ, Lurain J, Duplantis M, Veazey RS, Hope TJ: Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J Virol 2013; 87:1138811400.
  • 35
    Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:75527557.
  • 36
    Haase AT: Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2010; 62:127139.
  • 37
    Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigart O, Mulenga J, Keele BF, Shaw GM, Hahn BH, Allen SA, Derdeyn CA, Hunter E: Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009; 5:e1000274.
  • 38
    Sharkey DJ, Tremellen KP, Jasper MJ, Gemzell-Danielsson K, Robertson SA: Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol 2012; 188:24452454.
  • 39
    Balandya E, Wieland-Alter W, Sanders K, Lahey T: Human seminal plasma fosters CD4(+) regulatory T-cell phenotype and transforming growth factor-beta1 expression. Am J Reprod Immunol 2012; 68:322330.
  • 40
    Eschenbach DA, Patton DL, Hooton TM, Meier AS, Stapleton A, Aura J, Agnew K: Effects of vaginal intercourse with and without a condom on vaginal flora and vaginal epithelium. J Infect Dis 2001; 183:913918.
  • 41
    Astrup BS, Ravn P, Lauritsen J, Thomsen JL: Nature, frequency and duration of genital lesions after consensual sexual intercourse–implications for legal proceedings. Forensic Sci Int 2012; 219:5056.
  • 42
    Jones JS, Rossman L, Hartman M, Alexander CC: Anogenital injuries in adolescents after consensual sexual intercourse. Acad Emerg Med 2003; 10:13781383.
  • 43
    Ghosh M, Rodriguez-Garcia M, Wira CR: Immunobiology of genital tract trauma: endocrine regulation of HIV acquisition in women following sexual assault or genital tract mutilation. Am J Reprod Immunol 2013; 69 (Suppl 1):5160.
  • 44
    Berman JR, Bassuk J: Physiology and pathophysiology of female sexual function and dysfunction. World J Urol 2002; 20:111118.
  • 45
    Barnhart KT, Pretorius ES, Timbers K, Shera D, Shabbout M, Malamud D: In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception 2004; 70:498505.
  • 46
    Barnhart K, Kulp JL, Rosen M, Shera DM: A randomized trial to determine the distribution of four topical gel formulations in the human vagina. Contraception 2009; 79:297303.
  • 47
    Schwebke JR, Venglarik MF, Morgan SC: Delayed versus immediate bedside inoculation of culture media for diagnosis of vaginal trichomonosis. J Clin Microbiol 1999; 37:23692370.
  • 48
    Mitchell C, Manhart LE, Thomas KK, Agnew K, Marrazzo JM: Effect of sexual activity on vaginal colonization with hydrogen peroxide-producing lactobacilli and Gardnerella vaginalis. Sex Transm Dis 2011; 38:11371144.
  • 49
    Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, Chohan B, Mandaliya K, Ndinya-Achola JO, Bwayo J, Kreiss J: Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180:18631868.
  • 50
    Baeten J, Hassan W, Chohan V, Richardson BA, Mandaliya K, Ndinya-Achola JO, Jaoko W, McClelland RS: Prospective study of correlates of vaginal Lactobacillus colonization among high-risk HIV-1 seronegative women. Sex Transm Infect 2009; 85:348353.
  • 51
    Newton ER, Piper JM, Shain RN, Perdue ST, Peairs W: Predictors of the vaginal microflora. Am J Obstet Gynecol 2001; 184:845853 discussion 53–55.
  • 52
    Ma L, Lv Z, Su J, Wang J, Yan D, Wei J, Pei S: Consistent condom use increases the colonization of Lactobacillus crispatus in the vagina. PLoS One 2013; 8:e70716.
  • 53
    Sabatte J, Lenicov FR, Cabrini M, Rodriguez Rodrigues C, Ostrowski M, Ceballos A, Amigorena S, Geffner J: The role of semen in sexual transmission of HIV: beyond a carrier for virus particles. Microbes Infect 2011; 13:977982.
  • 54
    O'Connor TJ, Kinchington D, Kangro HO, Jeffries DJ: The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro. Int J STD AIDS 1995; 6:267272.
  • 55
    Martellini JA, Cole AL, Venkataraman N, Quinn GA, Svoboda P, Gangrade BK, Pohl J, Sørensen OE, Cole AM: Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma. FASEB J 2009; 23:36093618.
  • 56
    Agarwal A, Prabakaran SA: Mechanism, measurement, and prevention of oxidative stress in male reproductive physiology. Indian J Exp Biol 2005; 43:963974.
  • 57
    Sabatte J, Ceballos A, Raiden S, Vermeulen M, Nahmod K, Maggini J, Salamone G, Salomón H, Amigorena S, Geffner J: Human seminal plasma abrogates the capture and transmission of human immunodeficiency virus type 1 to CD4+ T cells mediated by DC-SIGN. J Virol 2007; 81:1372313734.
  • 58
    Stax MJ, van Montfort T, Sprenger RR, Melchers M, Sanders RW, van Leeuwen E, Repping S, Pollakis G, Speijer D, Paxton WA: Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytes. Virology 2009; 391:203211.
  • 59
    Balandya E, Sheth S, Sanders K, Wieland-Alter W, Lahey T: Semen protects CD4+ target cells from HIV infection but promotes the preferential transmission of R5 tropic HIV. J Immunol 2010; 185:75967604.
  • 60
    Keogan S, Wigdahl B, Krebs F: Human seminal fluid contains factors that modulate cervicovaginal epithelial monolayer integrity and may have roles in male-to-female transmission. 2012 International Microbicides Conference. Sydney, Australia, 2012.
  • 61
    Fox CA, Meldrum SJ, Watson BW: Continuous measurement by radio-telemetry of vaginal pH during human coitus. J Reprod Fertil 1973; 33:6975.
  • 62
    Bouvet JP, Gresenguet G, Belec L: Vaginal pH neutralization by semen as a cofactor of HIV transmission. Clin Microbiol Infect 1997; 3:1923.
  • 63
    Tevi-Benissan C, Belec L, Levy M, Schneider-Fauveau V, Si Mohamed A, Hallouin MC, Matta M, Grésenguet G: In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol 1997; 4:367374.
  • 64
    Ongradi J, Ceccherini-Nelli L, Pistello M, Specter S, Bendinelli M: Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications. AIDS Res Hum Retroviruses 1990; 6:14331436.
  • 65
    Lai SK, Hida K, Shukair S, Wang YY, Figueiredo A, Cone R, Hope TJ, Hanes J: Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 2009; 83:1119611200.
  • 66
    Aldunate M, Tyssen D, Johnson A, Zakir T, Sonza S, Moench T, Cone R, Tachedjian G: Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother 2013; 68:20152025.
  • 67
    Kim KA, Yolamanova M, Zirafi O, Roan NR, Staendker L, Forssmann WG, Burgener A, Dejucq-Rainsford N, Hahn BH, Shaw GM, Greene WC, Kirchhoff F, Münch J: Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology 2010; 7:55.
  • 68
    Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, Giménez-Gallego G, Sánchez PC, Fowler DM, Koulov A, Kelly JW, Mothes W, Grivel JC, Margolis L, Keppler OT, Forssmann WG, Kirchhoff F: Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007; 131:10591071.
  • 69
    Roan NR, Munch J, Arhel N, Mothes W, Neidleman J, Kobayashi A, Smith-McCune K, Kirchhoff F, Greene WC: The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J Virol 2009; 83:7380.
  • 70
    Roan NR, Muller JA, Liu H, Chu S, Arnold F, Stürzel CM, Walther P, Dong M, Witkowska HE, Kirchhoff F, Münch J, Greene WC: Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe 2011; 10:541550.
  • 71
    Easterhoff D, Ontiveros F, Brooks LR, Kim Y, Ross B, Silva JN, Olsen JS, Feng C, Hardy DJ, Dunman PM, Dewhurst S: Semen-derived enhancer of viral infection (SEVI) binds bacteria, enhances bacterial phagocytosis by macrophages, and can protect against vaginal infection by a sexually transmitted bacterial pathogen. Antimicrob Agents Chemother 2013; 57:24432450.
  • 72
    Ceballos A, Remes Lenicov F, Sabatte J, Rodríguez Rodrígues C, Cabrini M, Jancic C, Raiden S, Donaldson M, Agustín Pasqualini R Jr, Marin-Briggiler C, Vazquez-Levin M, Capani F, Amigorena S, Geffner J: Spermatozoa capture HIV-1 through heparan sulfate and efficiently transmit the virus to dendritic cells. J Exp Med 2009; 206:27172733.
  • 73
    Bouhlal H, Chomont N, Haeffner-Cavaillon N, Kazatchkine MD, Belec L, Hocini H: Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol 2002; 169:33013306.
  • 74
    Berlier W, Cremel M, Hamzeh H, Lévy R, Lucht F, Bourlet T, Pozzetto B, Delézay O: Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: involvement in the sexual transmission of HIV. Hum Reprod 2006; 21:11351142.
  • 75
    Kafka JK, Sheth PM, Nazli A, Osborne BJ, Kovacs C, Kaul R, Kaushic C: Endometrial epithelial cell response to semen from HIV-infected men during different stages of infection is distinct and can drive HIV-1-long terminal repeat. AIDS 2012; 26:2736.
  • 76
    Anderson JA, Ping LH, Dibben O, Jabara CB, Arney L, Kincer L, Tang Y, Hobbs M, Hoffman I, Kazembe P, Jones CD, Borrow P, Fiscus S, Cohen MS, Swanstrom R: HIV-1 populations in semen arise through multiple mechanisms. PLoS Pathog 2010; 6:e1001053.
  • 77
    Miller CJ, Marthas M, Torten J, Alexander NJ, Moore JP, Doncel GF, Hendrickx AG: Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia 1. J Virol 1994; 68:63916400.
  • 78
    Neildez O, Le Grand R, Cheret A, Caufour P, Vaslin B, Matheux F, Théodoro F, Roques P, Dormont D: Variation in virological parameters and antibody responses in macaques after atraumatic vaginal exposure to a pathogenic primary isolate of SIVmac251. Res Virol 1998; 149:5368.
  • 79
    Haase AT: Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011; 62:127139.
  • 80
    Roberts L, Passmore JA, Mlisana K, Williamson C, Little F, Bebell LM, Walzl G, Abrahams MR, Woodman Z, Abdool Karim Q, Abdool Karim SS: Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis 2012; 205:194203.
  • 81
    Politch JA, Tucker L, Bowman FP, Anderson DJ: Concentrations and significance of cytokines and other immunologic factors in semen of healthy fertile men. Hum Reprod 2007; 22:29282935.
  • 82
    Lisco A, Munawwar A, Introini A, Vanpouille C, Saba E, Feng X, Grivel JC, Singh S, Margolis L: Semen of HIV-1-infected individuals: local shedding of herpesviruses and reprogrammed cytokine network. J Infect Dis 2012; 205:97105.
  • 83
    Denison FC, Calder AA, Kelly RW: The action of prostaglandin E2 on the human cervix: stimulation of interleukin 8 and inhibition of secretory leukocyte protease inhibitor. Am J Obstet Gynecol 1999; 180:614620.
  • 84
    Zalenskaya I: Manuscript in preparation. 2013.
  • 85
    Narimatsu R, Wolday D, Patterson BK: IL-8 increases transmission of HIV type 1 in cervical explant tissue 1. AIDS Res Hum Retroviruses 2005; 21:228233.
  • 86
    Monteiro P, Gosselin A, Wacleche VS, El-Far M, Said EA, Kared H, Grandvaux N, Boulassel MR, Routy JP, Ancuta P: Memory CCR6+CD4+ T cells are preferential targets for productive HIV type 1 infection regardless of their expression of integrin beta7. J Immunol 2011; 186:46184630.
  • 87
    Dieu-Nosjean MC, Massacrier C, Homey B, Vanbervliet B, Pin JJ, Vicari A, Lebecque S, Dezutter-Dambuyant C, Schmitt D, Zlotnik A, Caux C: Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 2000; 192:705718.
  • 88
    Kawamura T, Kurtz SE, Blauvelt A, Shimada S: The role of Langerhans cells in the sexual transmission of HIV. J Dermatol Sci 2005; 40:147155.
  • 89
    Lekkerkerker AN, van Kooyk Y, Geijtenbeek TB: Viral piracy: HIV-1 targets dendritic cells for transmission. Curr HIV Res 2006; 4:169176.
  • 90
    de Witte L, Nabatov A, Pion M, Fluitsma D, de Jong MA, de Gruijl T, Piguet V, van Kooyk Y, Geijtenbeek TB: Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med 2007; 13:367371.
  • 91
    Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura T, Sakaguchi N, Sakaguchi S: Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007; 204:28032812.
  • 92
    Hirata T, Osuga Y, Takamura M, Kodama A, Hirota Y, Koga K, Yoshino O, Harada M, Takemura Y, Yano T, Taketani Y: Recruitment of CCR6-expressing Th17 cells by CCL 20 secreted from IL-1 beta-, TNF-alpha-, and IL-17A-stimulated endometriotic stromal cells. Endocrinology 2010; 151:54685476.
  • 93
    Miossec P: IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009; 11:625630.
  • 94
    El Hed A, Khaitan A, Kozhaya L, Manel N, Daskalakis D, Borkowsky W, Valentine F, Littman DR, Unutmaz D: Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis 2011; 201:843854.
  • 95
    Kader M, Wang X, Piatak M, Lifson J, Roederer M, Veazey R, Mattapallil JJ: Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2009; 2:439449.
  • 96
    McKinnon LR, Nyanga B, Chege D, Izulla P, Kimani M, Huibner S, Gelmon L, Block KE, Cicala C, Anzala AO, Arthos J, Kimani J, Kaul R: Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol 2011; 187:60326042.
  • 97
    Prendergast A, Prado JG, Kang YH, Chen F, Riddell LA, Luzzi G, Goulder P, Klenerman P: HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS 2010; 24:491502.
  • 98
    Ghosh M, Shen Z, Schaefer TM, Fahey JV, Gupta P, Wira CR: CCL20/MIP3alpha is a novel anti-HIV-1 molecule of the human female reproductive tract. Am J Reprod Immunol 2009; 62:6071.
  • 99
    Alexander NJ, Anderson DJ: Immunology of semen. Fertil Steril 1987; 47:192205.
  • 100
    Robertson SA, Ingman WV, O'Leary S, Sharkey DJ, Tremellen KP: Transforming growth factor beta–a mediator of immune deviation in seminal plasma. J Reprod Immunol 2002; 57:109128.
  • 101
    Lisco A, Introini A, Munawwar A, Vanpouille C, Grivel JC, Blank P, Singh S, Margolis L: HIV-1 imposes rigidity on blood and semen cytokine networks. Am J Reprod Immunol 2012; 68:515521.
  • 102
    Maegawa M, Kamada M, Irahara M, Yamamoto S, Yoshikawa S, Kasai Y, Ohmoto Y, Gima H, Thaler CJ, Aono T: A repertoire of cytokines in human seminal plasma. J Reprod Immunol 2002; 54:3342.
  • 103
    Carrette F, Surh CD: IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Immunol 2012; 24:209217.
  • 104
    Park JH, Yu Q, Erman B, Appelbaum JS, Montoya-Durango D, Grimes HL, Singer A: Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 2004; 21:289302.
  • 105
    Beq S, Delfraissy JF, Theze J: Interleukin-7 (IL-7): immune function, involvement in the pathogenesis of HIV infection and therapeutic potential. Eur Cytokine Netw 2004; 15:279289.
  • 106
    Crawley AM, Angel JB: The influence of HIV on CD127 expression and its potential implications for IL-7 therapy. Semin Immunol 2012; 24:231240.
  • 107
    Introini A, Vanpouille C, Lisco A, Grivel JC, Margolis L: Interleukin-7 facilitates HIV-1 transmission to cervico-vaginal tissue ex vivo. PLoS Pathog 2013; 9:e1003148.
  • 108
    Vassena L, Miao H, Cimbro R, Malnati MS, Cassina G, Proschan MA, Hirsch VM, Lafont BA, Morre M, Fauci AS, Lusso P: Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques. PLoS Pathog 2012; 8:e1002636.
  • 109
    Wahl SM: Transforming growth factor-beta: innately bipolar. Curr Opin Immunol 2007; 19:5562.
  • 110
    Kelly RW: Immunosuppressive mechanisms in semen: implications for contraception. Hum Reprod 1995; 10:16861693.
  • 111
    Sharkey DJ, Macpherson AM, Tremellen KP, Mottershead DG, Gilchrist RB, Robertson SA: TGF-beta mediates proinflammatory seminal fluid signaling in human cervical epithelial cells. J Immunol 2012; 189:10241035.
  • 112
    Lotz M, Seth P: TGF beta and HIV infection. Ann N Y Acad Sci 1993; 685:501511.
  • 113
    Lazdins JK, Klimkait T, Alteri E, Walker M, Woods-Cook K, Cox D, Bilbe G, Shipman R, Cerletti N, McMaster G: TGF-beta: upregulator of HIV replication in macrophages. Res Virol 1991; 142:239242.
  • 114
    Lazdins JK, Klimkait T, Woods-Cook K, Walker M, Alteri E, Cox D, Cerletti N, Shipman R, Bilbe G, McMaster G.: In vitro effect of transforming growth factor-beta on progression of HIV-1 infection in primary mononuclear phagocytes. J Immunol 1991; 147:12011207.
  • 115
    Poli G, Kinter AL, Justement JS, Bressler P, Kehrl JH, Fauci AS: Transforming growth factor beta suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte/macrophage lineage. J Exp Med 1991; 173:589597.
  • 116
    Li JM, Shen X, Hu PP, Wang XF: Transforming growth factor beta stimulates the human immunodeficiency virus 1 enhancer and requires NF-kappaB activity. Mol Cell Biol 1998; 18:110121.
  • 117
    Moriuchi M, Moriuchi H: Seminal fluid enhances replication of human T-cell leukemia virus type 1: implications for sexual transmission. J Virol 2004; 78:1270912711.
  • 118
    Harizi H, Grosset C, Gualde N: Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. J Leukoc Biol 2003; 73:756763.
  • 119
    Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, Narumiya S: Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 2003; 9:744749.
  • 120
    Tilley SL, Coffman TM, Koller BH: Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108:1523.
  • 121
    Sakata D, Yao C, Narumiya S: Prostaglandin E2, an immunoactivator. J Pharmacol Sci 2010; 112:15.
  • 122
    Bankhurst AD: The modulation of human natural killer cell activity by prostaglandins. J Clin Lab Immunol 1982; 7:8591.
  • 123
    Kalinski P: Regulation of immune responses by prostaglandin E2. J Immunol 2012; 188:2128.
  • 124
    Templeton AA, Cooper I, Kelly RW: Prostaglandin concentrations in the semen of fertile men. J Reprod Fertil 1978; 52:147150.
  • 125
    Sales KJ, Katz AA, Millar RP, Jabbour HN: Seminal plasma activates cyclooxygenase-2 and prostaglandin E2 receptor expression and signalling in cervical adenocarcinoma cells. Mol Hum Reprod 2002; 8:10651070.
  • 126
    Joseph T, Zalenskaya IA, Yousefieh N, Schriver SD, Cote LC, Chandra N, Doncel GF: Induction of cyclooxygenase (COX)-2 in human vaginal epithelial cells in response to TLR ligands and TNF-alpha. Am J Reprod Immunol 2012; 67:482490.
  • 127
    Baba M: Recent status of HIV-1 gene expression inhibitors. Antiviral Res 2006; 71:301306.